BeyondSpring (BYSI) Receivables - Other (2018 - 2019)
BeyondSpring's (BYSI) quarterly Receivables - Other came in at $381000.0 in Q1 2019, down 20.79% quarter-over-quarter from $481000.0 in Q4 2018.
Powered by 
Analysis
BeyondSpring (BYSI) Receivables - Other (2018 - 2019) Analysis & Trends
BeyondSpring has disclosed Receivables - Other across 2 years of filings, most recently posting $381000.0 for Q1 2019.
- In Q1 2019, Receivables - Other changed N/A year-over-year to $381000.0; the TTM figure through Mar 2019 stood at $381000.0 (changed N/A YoY), while the FY2018 annual figure was $481000.0, changed N/A from the prior year.
- Receivables - Other came in at $381000.0 for Q1 2019 at BeyondSpring, down from $481000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $481000.0 in Q4 2018 to a low of $381000.0 in Q1 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn |
| 10 | BeyondSpring | 31.51 Mn | 31.51 Mn | - |